<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252368</url>
  </required_header>
  <id_info>
    <org_study_id>EK-1744</org_study_id>
    <nct_id>NCT01252368</nct_id>
  </id_info>
  <brief_title>Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)</brief_title>
  <official_title>Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      Aim of this trial is to investigate the expression and localisation of different amino acid&#xD;
      transporters and their regulatory proteins derived from the regulatory proteins of the local&#xD;
      renin angiotensin system (RAS) in the intestine. This is investigated on one hand in patients&#xD;
      who do not take any drugs interfering with RAS. On the other hand expression analysis is done&#xD;
      in patients taking daily RAS-active drugs, like ACE inhibitors or sartanes.&#xD;
&#xD;
      After obtaining informed consent of patients attending the hospital for clarification of&#xD;
      gastrointestinal symptoms by gastroduodenoscopy or colonoscopy, 2 biopsies (in addition to&#xD;
      biopsies needed for clinical diagnostics) will be taken from each duodenum, jejunum, ileum&#xD;
      and descending colon.&#xD;
&#xD;
      Biopsies are investigated anonymously at the Institute of Physiology of the University of&#xD;
      Zurich. The mRNA content of amino acid transporters and regulatory proteins, respectively, in&#xD;
      the biopsies is analyzed by quantitative PCR. Transport proteins are in addition analyzed&#xD;
      with immunohistochemistry.&#xD;
&#xD;
      Furthermore amino acid concentration in plasma and urine samples are analyzed by HPLC. From&#xD;
      plasma and serum samples RAS parameters like renin, aldosterone, ACE and angiotensin(1-7) are&#xD;
      measured.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Participants</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>RAS active drugs</arm_group_label>
    <description>ACE inhibitors and sartanes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy participants</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hypertension</intervention_name>
    <description>patients taking daily ACE inhibitors or sartanes</description>
    <arm_group_label>RAS active drugs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending the hospital for clarification of gastrointestinal symptoms by&#xD;
        gastroduodenoscopy or colonoscopy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Men and women aged 18-80 years&#xD;
&#xD;
          -  BMI 18-35 kg/m2&#xD;
&#xD;
          -  Group 1: patients taking daily RAS-active drugs, like ACE inhibitors or sartanes&#xD;
             (treatment indication outside of this study)&#xD;
&#xD;
          -  Group 2: no therapy with RAS-active drugs, like ACE inhibitors or sartanes&#xD;
             Gastroduodenoscopy and/or colonoscopy with a treatment indication outside of this&#xD;
             study&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Severe pathologic alterations in the gastrointestinal tract (ulcers, tumors, celiac&#xD;
             disease; GERD and gastritis are no exclusion criteria)&#xD;
&#xD;
          -  Status after operations of the gastrointestinal tract (except uncomplicated&#xD;
             appendectomy or inguinal hernia repair)&#xD;
&#xD;
          -  Patients with malignant diseases&#xD;
&#xD;
          -  Severe acute or chronic diseases which require treatment (e.g. renal replacement&#xD;
             therapy)&#xD;
&#xD;
          -  Patients with increased bleeding risk (e.g. oral anticoagulation, coagulopathy)&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Mental disorders which limits the ability to fulfil all study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Schwizer, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Gastroenterology and Hepatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Gastroenterology and Hepatology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

